ESG Report 2024

25 Environmental, Social and Governance Report 2024 The United Laboratories International Holdings Limited Production Application Clinical Trial Clinical Trial Application Pre-clinical R&D Stage: R&D Pipeline Indications Project R&D Stage Lp ( a ) Hypolipidemic Drugs* Sodium Hyaluronate Eye Drops GLP - 1 Oral Preparation* Interleukin - 2 Fusion Protein* Anti - IL - 4R Monoclonal Antibody UBT251 Injection* UBT38006* Diabetes Insulin Degludec Injection Semaglutide Injection Insulin Degludec and Insulin Aspart Injection UBT251 Injection* UBT37034* Diabetes Obesity Eczema Asthma & SLE , etc Conjunctivitis Semaglutide Injection Romosozumab Injection MAFLD Obesity LB2237* LB2012 * Hyperlipemia Xerophthalmia TUL12101 Eye Drops * Bacterial Infection LB2311* LB2343* Fungal Infection LB2332 * LB2249 * Fat Loss and Muscle Gain Xerophthalmia Weight Loss / Avoid weight rebound Diabetes Obesity & LB2023* IgA Nephritis TUL01101 Tablets* IBD Insulin Degludec / Liraglutide Injection sgp130 - Fc Fusion Protein* Hyperlipoproteinemia , etc . UBT251 Injection* UBT251 Injection* Anti - IL - 4Ra / TSLP Bispecific Antibody* Osteoporosis TUL01101 Tablets* Rheumatoid Arthritis TUL01101 Ointment* Atopic Dermatitis Demodex Blepharitis LB2149 Olopatadine Hydrochloride Nasal Spray Olopatadine Hydrochloride Eye Drops Moxifloxacin Hydrochloride Eye Drops Levofloxacin Eye Drops Acetylcysteine Effervescent Tablets Sivelestat Sodium for Injection Respiratory Infection Acute pulmonary injury , etc . Allergic Rhinitis Symptom Alendronate Sodium Vitamin D3 Tablets Clenbuterol Ointment Atopic Dermatitis Osteoporosis Finerenone Tablets Diabetic Nephropathy Overweight / Obesity Multi - Vitamin Tablets Tadalafil Tablets Male Dysfunction Nutritional Supplement Mabrasvir Tablets Type A / B Influenza CKD (BE)